TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36205580

Group type: EXPERIMENTAL
Intervention: Immediate Surgery (IS)
Number of subjects: 4635

Group type: COMPARATOR
Intervention: Conversion Surgery (CS)
Number of subjects: 4635

Group type: COMPARATOR
Intervention: Active Surveillance (AS)
Number of subjects: 4635
Study: 34107936

Group type: EXPERIMENTAL
Intervention: Simulation-based training (Group S)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Video-based training (Group V)
Number of subjects: 120
Study: 32795282

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST) program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 93
Study: 36288651

Group type: EXPERIMENTAL
Intervention: Jingyin granules (JY)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study: 33764417

Group type: EXPERIMENTAL
Intervention: Internet-based exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32769658

Group type: EXPERIMENTAL
Intervention: Outpatient transcervical Foley catheter
Number of subjects: 126

Group type: COMPARATOR
Intervention: Inpatient transcervical Foley catheter
Number of subjects: 126
Study: 616651636

Group type: EXPERIMENTAL
Intervention: FDA-proposed warnings with pictures illustrating the smoking hazards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warnings with the same text information paired with equally aversive but smoking‐irrelevant images
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 0
Study: 35857211

Group type: EXPERIMENTAL
Intervention: Yogurt mixed with ioversol
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Lotus root powder mixed with ioversol
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Gas-producing powder
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (pure iodine water)
Number of subjects: 136
Study: 34246130

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (MCT) with doses of PC20 ? 8 mg/ml
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (MCT) with doses of PC20 ? 2 mg/ml
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Combination of asthmatic wheeze and BHR
Number of subjects: 684
Study: 35257222

Group type: EXPERIMENTAL
Intervention: Adhesive, non-impregnated drape applied to the skin prior to incision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (surgery without a drape)
Number of subjects: 100
Study: 32933543

Group type: EXPERIMENTAL
Intervention: GRU-RNN predictive model (Experimental Plans - EPs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical Plans (CPs)
Number of subjects: 100
Study: 34825503

Group type: EXPERIMENTAL
Intervention: Weight Bias Reduction training enhanced by case-based learning (WBR-I, n=7)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard Weight Bias Reduction training (Control, n=6)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weight Bias Reduction training (both groups)
Number of subjects: 42
Study: 35420865

Group type: EXPERIMENTAL
Intervention: Prefactual thinking about how a falsehood might become true in the future
Number of subjects: 3607

Group type: EXPERIMENTAL
Intervention: Prefactual thinking
Number of subjects: 3607
Study: 32229029

Group type: EXPERIMENTAL
Intervention: MTA with Er,Cr:YSGG laser
Number of subjects: 90

Group type: COMPARATOR
Intervention: MTA alone
Number of subjects: 90
Study: 36111910

Group type: EXPERIMENTAL
Intervention: Concurrent aerobic and resistance exercises (three sessions per week for twelve weeks on alternative days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Regular lifestyle practices and medical treatment without any exercise intervention
Number of subjects: 43
Study: 34453891

Group type: EXPERIMENTAL
Intervention: Repeated strand invasion and extensive branch migration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crossover-specific double Holliday junction formation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncrossover and crossover recombinants
Number of subjects: 0
Study: 33775175

Group type: EXPERIMENTAL
Intervention: Caregiver-guided pain coping skills training
Number of subjects: 202

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual control
Number of subjects: 202
Study: 33039447

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 33436463

Group type: EXPERIMENTAL
Intervention: Carer Support Needs Assessment Tool for Stroke
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 414
Study: 34223660

Group type: COMPARATOR
Intervention: CBD 200 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: CBD 400 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: CBD 800 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: CBD (all doses)
Number of subjects: 17
Study: 35776835

Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg extended-release tablets)
Number of subjects: 21
Study: 34038229

Group type: EXPERIMENTAL
Intervention: Vignette with potentially traumatic event (PTE)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Vignette without potentially traumatic event (PTE)
Number of subjects: 266
Study: 33278717

Group type: EXPERIMENTAL
Intervention: Peer-led intervention (random and assigned peer-leaders)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Expert-led intervention
Number of subjects: 686
Study: 34283710

Group type: EXPERIMENTAL
Intervention: Oxytocin massage
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 73
Study: 34170526

Group type: EXPERIMENTAL
Intervention: Fitspiration images (N = 233)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Travel images (N = 209)
Number of subjects: 442
Study: 36099926

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg, intravenous, once every 3 weeks for 16 cycles or 1 year)
Number of subjects: 778

Group type: COMPARATOR
Intervention: Placebo (intravenous, once every 3 weeks for 16 cycles or 1 year)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study: 34144032

Group type: EXPERIMENTAL
Intervention: High-dose Erythropoietin for Asphyxia and Encephalopathy Trial
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acute abnormalities
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Chronic abnormalities
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Chronic placental abnormalities
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Acute placental lesions
Number of subjects: 500
Study: 32581367

Group type: EXPERIMENTAL
Intervention: CMS4 tumors
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: MSI tumors
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Low immunoscore tumors
Number of subjects: 651
Study: 33749155

Group type: EXPERIMENTAL
Intervention: Last positive HIV test during breastfeeding
Number of subjects: 822

Group type: COMPARATOR
Intervention: Last positive HIV test during pregnancy
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Last positive HIV test during breastfeeding with travel time >2 hours to health facility
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Last positive HIV test during breastfeeding with travel time 1-2 hours to health facility
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Last positive HIV test during breastfeeding vs pregnancy
Number of subjects: 822
Study: 35581709

Group type: EXPERIMENTAL
Intervention: Video laryngoscope
Number of subjects: 120

Group type: COMPARATOR
Intervention: USB borescope
Number of subjects: 120
Study: 33399006

Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance measured by catheterization or approximated from ultrasound data
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Composite clinical score
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 6-minute walk test distance
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 222
Study: 32893710

Group type: EXPERIMENTAL
Intervention: Vegetarian Diet (VD)
Number of subjects: 31
Study: 35728359

Group type: EXPERIMENTAL
Intervention: Fewer thought probes (1-6 probes) during an operation span task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fewer thought probes (1-6 probes) during a video lecture
Number of subjects: 0
Study: 32921425

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) therapy as an add-on treatment, 2 to 10 mg, for a long period.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) therapy, 2 mg slow release, 1 to 2 hours before bedtime, for 3 to 12 weeks.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Immediate release MEL prescribed for REM sleep behavior disorder.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) in Parkinson's disease with sleep disorders.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) in epileptic patients.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light therapy used 12 hours before melatonin treatment.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Melatonin (MEL) in primary headache, migraine, and cluster headache.
Number of subjects: 11
Study: 32777381

Group type: EXPERIMENTAL
Intervention: Automated bilingual computerized alcohol screening and brief intervention (AB-CASI)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: AB-CASI
Number of subjects: 820
Study: 35588339

Group type: EXPERIMENTAL
Intervention: u-net model for tumor segmentation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Expert visual ratings
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Real-time tumor segmentation
Number of subjects: 33
Study: 33128325

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 120
Study: 35578445

Group type: EXPERIMENTAL
Intervention: Combination therapy of tofogliflozin (20 mg) and pioglitazone (15–30 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 32
Study: 32694366

Group type: EXPERIMENTAL
Intervention: Functional Impact Training (FIT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Yin Yoga
Number of subjects: 44

Group type: COMPARATOR
Intervention: Functional Impact Training (FIT) and Yin Yoga
Number of subjects: 44
Study: 35078735

Group type: EXPERIMENTAL
Intervention: Nurse practitioner-delivered brief intervention (BI)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Computer-delivered brief intervention (BI)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Nurse practitioner-delivered BI
Number of subjects: 254
Study: 32648392

Group type: EXPERIMENTAL
Intervention: Meridian-point acupuncture group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Medication group (estazolam 1-2 mg per night for 4 weeks)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 140
Study: 34534371

Group type: EXPERIMENTAL
Intervention: Báa nnilah chronic illness self‐management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 33417708

Group type: EXPERIMENTAL
Intervention: Proximity to neighborhood investments (<0.1 mile)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Farther away from neighborhood investments (>0.1 mile)
Number of subjects: 676
Study: 32211798

Group type: EXPERIMENTAL
Intervention: Milk8 (8.8 g milk protein/d, 100 kcal/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk/rice (4.4 g milk and 4.4 g rice protein/d, 100 kcal/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk4 (4.4 g milk protein/d, 48 kcal/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no protein, 10 kcal/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk interventions (general)
Number of subjects: 0
Study: 35994240

Group type: EXPERIMENTAL
Intervention: Health education via mobile application
Number of subjects: 214

Group type: COMPARATOR
Intervention: Face-to-face health education (control group)
Number of subjects: 214
Study: 34370858

Group type: EXPERIMENTAL
Intervention: Ultra-long downregulation with GnRH agonist (triptorelin depot) for at least 3 months followed by ART stimulation.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group underwent ART stimulation in a classical long agonist protocol using oral contraceptives.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ultra-long group (I)
Number of subjects: 42
Study: 32881761

Group type: EXPERIMENTAL
Intervention: Paro robot (multisensory enrichment)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Music (auditory enrichment)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 105
Study: 36320646

Group type: EXPERIMENTAL
Intervention: Cardiac CTA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 33035687

Group type: EXPERIMENTAL
Intervention: c-terminal FGF23 (cFGF23) levels
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: intact FGF23 (iFGF23) levels
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Longitudinal outcomes
Number of subjects: 172
Study: 33046514

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 106
Study: 32443343

Group type: EXPERIMENTAL
Intervention: Twice-weekly MHD
Number of subjects: 140

Group type: COMPARATOR
Intervention: 3-times-weekly MHD
Number of subjects: 140
Study: 36058996

Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux DCB (Biotronik)
Number of subjects: 302

Group type: COMPARATOR
Intervention: IN.PACT Admiral DCB (Medtronic)
Number of subjects: 302
Study: 34346046

Group type: EXPERIMENTAL
Intervention: Duloxetine 20mg/daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Solifenacin 10mg/daily
Number of subjects: 60
Study: 32715455

Group type: EXPERIMENTAL
Intervention: Vacuum‐assisted Access Sheath (VAAS) combined with holmium laser lithotripsy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amplatz sheath combined with Cyberwand double probe ultrasound lithotripsy
Number of subjects: 76
Study: 35346339

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy for a minimum of 16 hours immediately post extubation
Number of subjects: 850

Group type: COMPARATOR
Intervention: Standard oxygen therapy for a minimum of 16 hours immediately post extubation
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy
Number of subjects: 850

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 850
Study: 33662489

Group type: EXPERIMENTAL
Intervention: High dose intermittent vitamin D3 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose B12 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (dietary instruction only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational group (normal vitamin D and B12 levels)
Number of subjects: 0
Study: 34740538

Group type: EXPERIMENTAL
Intervention: L-Carnitine 50 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 36036539

Group type: EXPERIMENTAL
Intervention: Efgartigimod (FcRn antagonist)
Number of subjects: 17
Study: 33098171

Group type: EXPERIMENTAL
Intervention: Millard technique for lip repair, von Langenbeck technique for palate repair, early palate repair (9 to 12 months)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Spina technique for lip repair, Furlow technique for palate repair, late palate repair (15 to 18 months)
Number of subjects: 448
Study: 34750197

Group type: EXPERIMENTAL
Intervention: Prehabilitation program plus ERAS standard preoperative care
Number of subjects: 194

Group type: COMPARATOR
Intervention: ERAS standard preoperative care
Number of subjects: 194
Study: 32818963

Group type: EXPERIMENTAL
Intervention: VT‐1161 300 mg once daily for 3 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: VT‐1161 600 mg once daily for 3 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: VT‐1161 600 mg twice daily for 3 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fluconazole 150 mg (single dose)
Number of subjects: 55
Study: 32677486

Group type: EXPERIMENTAL
Intervention: Swiss-roll folding method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Common folding method
Number of subjects: 100
Study: 33567901

Group type: EXPERIMENTAL
Intervention: Relationship distress
Number of subjects: 0
Study: 32196968

Group type: COMPARATOR
Intervention: Nutrition intervention arms (N)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water intervention arm (W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (C)
Number of subjects: 0
Study: 32929891

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg, 3 times per week for 16 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg, 3 times per week for 16 weeks (in AERD-negative patients)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (in AERD-negative patients)
Number of subjects: 128
Study: 32942967

Group type: EXPERIMENTAL
Intervention: Clinical data model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clinical + electroencephalography data using deep learning neural network model
Number of subjects: 100
Study: 35236423

Group type: EXPERIMENTAL
Intervention: Low-fat milk fortified with 1500 IU nano-encapsulated vitamin D3 (200 mL/day)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt fortified with 1500 IU nano-encapsulated vitamin D3 (150 g/day)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Simple milk (200 mL/day)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Simple yogurt (150 g/day)
Number of subjects: 289
Study: 32494991

Group type: EXPERIMENTAL
Intervention: Pharmacist-administered deprescribing intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study: 36270632

Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthetic (IPLA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Local anesthetic wound infiltration (LWI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 33905144

Group type: EXPERIMENTAL
Intervention: Subcutaneous nerve field stimulation in combination with optimized medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized medical management alone
Number of subjects: 0
Study: 32302526

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33894725

Group type: EXPERIMENTAL
Intervention: Reduning injection (20 mL/day for 14 days)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control (routine treatment without Reduning injection)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Reduning injection
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control
Number of subjects: 157
Study: 34586006

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff pressure maintained at 20 mmHg (Intervention Group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Passive monitoring of endotracheal tube cuff pressure (Control Group)
Number of subjects: 98
Study: 33764833

Group type: EXPERIMENTAL
Intervention: 50 mg or 100 mg of water-soluble CoQ10 (total daily dose, 100 mg [n = 5] or 200 mg [6])
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (7)
Number of subjects: 30
Study: 34642106

Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (single session)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 50
Study: 34848519

Group type: EXPERIMENTAL
Intervention: Rolling-refresher group (RRG) participated in very brief (5 min) rolling-refreshers every 4 months.
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Standard group (SG) received one 50 min retraining session 1 year later.
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (CG) did not receive any additional training.
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Rolling-refresher group (RRG)
Number of subjects: 472
Study: 32991462

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.1 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local infiltration anesthesia (LIA) with epinephrine, ketorolac acid, and ropivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local infiltration anesthesia (LIA)
Number of subjects: 80
Study: 34861430

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/d) and Vitamin D (1000 IU/d) supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34243767

Group type: EXPERIMENTAL
Intervention: Clinical simulations with simulated patients (SP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Role-playing (RP) scenario
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups (SP and RP)
Number of subjects: 42
Study: 35277034

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34793441

Group type: EXPERIMENTAL
Intervention: 500 mg iOWH032 every 8 hours for 3 days
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 34164873

Group type: EXPERIMENTAL
Intervention: Enforcement methodology (Authorised Inspectors)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Information and assistance methodology (general health service staff)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Enforcement methodology (groups of smokers)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Enforcement methodology (individual smokers)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall aggression measures
Number of subjects: 200